N. A. Lyzhko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
N. A. Lyzhko has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Laura A. Kesaeva
GeneTechnology
3 shared publications - Vsevolod Andreevich Misyurin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Olga N. Solopova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - V. V. Tikhonova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Yulia P. Finashutina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications A. A. Rudakova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication
Latest Publications
- Open Access
- 15 May 2019
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 6 (2)
Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
Molecular genetic detection of CALR gene somatic mutations is required for myeloproliferative neoplasms diagnosis and treatment according to the novel WHO clinical recommendations. CALR mutations are found in approximately 25–35 % cases of essential thrombocythemia and primary myelofibrosis and they are associated with benign clinical outcome. In this study we have compared sensitivity and selectivity of seve ral different options of CALR mutation molecular genetic detection in blood samples of 379 CMD patients and 17 healthy donors. Among methods compared in our study there have been conventional polymerase chain reaction with electrophoretic detection, real-time quantitative polymerase chain reaction, direct Sanger sequencing of polymerase chain reaction fragments and polymerase chain reaction high resolution melting curve analysis. By means of melting curve analysis CALR mutations have been found in 97 (25.5 %) patients, whereas in the cases of Sanger sequencing and polymerase chain reaction there have been 87 (23.0 %) and 84 (22.1 %) CALR mutation positive patients respectively.
- 15 May 2019
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 6 (2)
Open AccessComparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
Molecular genetic detection of CALR gene somatic mutations is required for myeloproliferative neoplasms diagnosis and treatment according to the novel WHO clinical recommendations. CALR mutations are found in approximately 25–35 % cases of essential thrombocythemia and primary myelofibrosis and they are associated with benign clinical outcome. In this study we have compared sensitivity and selectivity of seve ral different options of CALR mutation molecular genetic detection in blood samples of 379 CMD patients and 17 healthy donors. Among methods compared in our study there have been conventional polymerase chain reaction with electrophoretic detection, real-time quantitative polymerase chain reaction, direct Sanger sequencing of polymerase chain reaction fragments and polymerase chain reaction high resolution melting curve analysis. By means of melting curve analysis CALR mutations have been found in 97 (25.5 %) patients, whereas in the cases of Sanger sequencing and polymerase chain reaction there have been 87 (23.0 %) and 84 (22.1 %) CALR mutation positive patients respectively.
- Open Access
- 15 December 2018
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 5 (4) , 131-134
Chemoresistance of PRAME-expressing melanoma cell can be resolved with help of bortezomib
Background. PRAME gene spontaneous expression is frequently observed in a cancer cell. The protein encoded by this gene increases the viability of tumour cell. NF-κB signalling pathway takes part in PRAME upregulation. It proposes, that stress conditions may increase the expression level of PRAME in the tumour cell and increase cell’s viability after it. We hypothesized that this phenomenon determines chemoresistance of PRAME-expressing cell, which can be overcome by NF-κB inhibitors, such as bortezomib.Materials and methods. We incubated A875 melanoma cells with cisplatin, bortezomib and dexamethasone, as well as with a mixture of cisplatin with bortezomib and cisplatin with dexamethasone within 24 hours. To assess the cytotoxicity of these combinations MTT-test was used. For evaluation of PRAME expression level, real-time polymerase chain reaction was used. All data were analyzed with Wilcoxon test for coupled samples.Results. It was found that cisplatin and dexamethasone increased an expression level of PRAME compared to control (p 0.03). The addition of dexamethasone to cisplatin reduced cytotoxic effect of cisplatin. Bortezomib has a cytotoxic effect, but it did not increase the activity of PRAME gene (p = 0.12). PRAME gene activity in cells incubated with a mixture of cisplatin and bortezomib was observed at a lower level in comparison with cells incubated with cisplatin (p = 0.0277).Conclusion. The results of experiments show that an increase of PRAME expression level reduces the sensitivity of melanoma cells to the cytotoxic effect of cisplatin. PRAME activity increases under stress conditions. Using of bortezomib can inhibit the growth of PRAME expression and makes the tumour cell more vulnerable to cytotoxic agents. On the other hand, dexamethasone may increase a resistance of PRAME-expressing cell to cytotoxic effects.
- 15 December 2018
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 5 (4) , 131-134
Open AccessChemoresistance of PRAME-expressing melanoma cell can be resolved with help of bortezomib
Background. PRAME gene spontaneous expression is frequently observed in a cancer cell. The protein encoded by this gene increases the viability of tumour cell. NF-κB signalling pathway takes part in PRAME upregulation. It proposes, that stress conditions may increase the expression level of PRAME in the tumour cell and increase cell’s viability after it. We hypothesized that this phenomenon determines chemoresistance of PRAME-expressing cell, which can be overcome by NF-κB inhibitors, such as bortezomib.Materials and methods. We incubated A875 melanoma cells with cisplatin, bortezomib and dexamethasone, as well as with a mixture of cisplatin with bortezomib and cisplatin with dexamethasone within 24 hours. To assess the cytotoxicity of these combinations MTT-test was used. For evaluation of PRAME expression level, real-time polymerase chain reaction was used. All data were analyzed with Wilcoxon test for coupled samples.Results. It was found that cisplatin and dexamethasone increased an expression level of PRAME compared to control (p 0.03). The addition of dexamethasone to cisplatin reduced cytotoxic effect of cisplatin. Bortezomib has a cytotoxic effect, but it did not increase the activity of PRAME gene (p = 0.12). PRAME gene activity in cells incubated with a mixture of cisplatin and bortezomib was observed at a lower level in comparison with cells incubated with cisplatin (p = 0.0277).Conclusion. The results of experiments show that an increase of PRAME expression level reduces the sensitivity of melanoma cells to the cytotoxic effect of cisplatin. PRAME activity increases under stress conditions. Using of bortezomib can inhibit the growth of PRAME expression and makes the tumour cell more vulnerable to cytotoxic agents. On the other hand, dexamethasone may increase a resistance of PRAME-expressing cell to cytotoxic effects.